NEWS DETAIL

Qilu Pharmaceutical's New Anti-Tumor Drug QLS31901 Phase I Clinical Trial Targeting PD-L1/TGFβ Completed the First Subject Administration

Qilu Pharmaceutical's new anti-tumor drug QLS31901 Phase I clinical trial targeting PD-L1/TGFβ completed the first subject administration
2021/06/11 14:24:11
On June 10th, Qilu Pharmaceutical's new drug QLS31901, a new drug targeting PD-L1/TGFβ, completed its first clinical trial on June 2nd. This study was conducted in patients with advanced malignant tumors. It is intended to evaluate the safety, tolerability, and preliminary efficacy of QLS31901, and determine the recommended dose (RP2D) for the phase II clinical trial.

QLS31901 is a new type of biological product for PD-L1/TGF-β, as a bifunctional antibody-ligand capture fusion protein, one end is an antibody that can recognize and bind PD-L1, and the other end is a receptor for TGF-β, which can simultaneously antagonize TGF-β and PD-L1. Blocking the PD-L1 pathway and the TGF-β pathway at the same time can improve the tumor suppressive microenvironment, thereby enhancing the effect of cytotoxic T lymphocytes, promoting the killing of tumor cells by immune cells, and overcoming the effect of tumor cells on PD-1/PD- The resistance of L1 therapy to improve the effectiveness of anti-tumor drugs.

Tongyi Medicine pays attention to the cutting-edge policies of medicine and the latest developments in the research and development of new drugs at home and abroad.

Qilu Pharmaceutical has always adhered to the R&D-driven strategy, continued to increase scientific research investment in a high proportion, spared no effort to provide various world advanced software and hardware conditions for the advancement of drug research and development, and ensure the initiative of innovation. At the same time, the company closely follows the development trend of international innovative drugs and has established The international R&D system supported by the five major R&D platforms in China and the United States integrates global high-quality resources and continues to develop "global new" and "global good" drugs. Innovative drug product lines that have been laid out in the fields of tumors, autoimmunity, infections, metabolic diseases, liver diseases and other unsatisfied major diseases. In the next few years, a number of innovative drugs will be developed and marketed, providing a source for the company's high-quality development Constant motivation.

Disclaimer: The copyright belongs to the original, and this article is reproduced for the purpose of conveying more information. If your legal rights are violated, please contact this website, we will correct and delete it in time, thank you.
Tongyi Pharmaceutical (Suzhou) Co., Ltd. was established in March 2016, dedicated to the development and industrialization of tumor-targeted ligand-conjugated drugs and tumor biomarker diagnostic reagents. BestTM (Bi-Engaging ligand-mediated Selective Targeting), a multi-target drug conjugate technology platform pioneered by Tongyi Medicine, is the leader in the new class of anti-tumor conjugate drugs (XDC). Compared with antibodies and macromolecular ADC biological drugs, BESTTM technology overcomes the disadvantages of poor solid tumor penetration, limited indications, long development cycle, complex production process and high cost; compared with chemical drugs, coupling drugs are greatly reduced The toxicity of the drug. Early research results confirmed that BESTTM compounds have good efficacy and toxicological properties. The BESTTM technology platform has been patented in many countries around the world. Based on the company's BESTTM technology platform, Tongyi Pharmaceutical has developed a rich product pipeline. The first product, CBP-1008, has obtained China's clinical approval and US FDA clinical approval, and is in the phase I clinical research phase. The second product, CBP-1018, has obtained clinical approval from China's NMPA. In addition, many new drugs are in different stages of research and development, and will gradually enter clinical development in the next few years.